Opiate receptors grow back pet mri near

  • In this article we describe how opioids affect brain processes to produce drug liking, tolerance, dependence, and addiction.
  • This study provides initial characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone administration to healthy.
  • We aimed to provide direct human in vivo evidence for changes in opioid receptor availability following spontaneous seizures.

    • •

    Classifying migraine using PET compressive big data analytics of brain’s μ-opioid and D2/D3 dopamine neurotransmission

    Introduction

    Migraine is a pain disorder with a prevalence of more than one billion people worldwide (Global Burden of Disease GBD, 2017). It dramatically impacts the patients’ daily lives with frequent headache attacks, neuropsychiatric comorbidities, and the potential for substance abuse when unremitted, especially opiates (Bigal et al., 2009; Buse et al., 2012; Adams et al., 2015; Lipton et al., 2020). Because of this significant sensory and cognitive-motivational dysregulation in migraine, the endogenous μ-opioid and D2/D3 dopamine (DA) molecular mechanisms have recently been investigated as the potential main culprits of the disorder (Zubieta et al., 2002; De Felice et al., 2013; Martikainen et al., 2013; Jassar et al., 2019). Pharmacologically, they are the targets for the action of the most potent exogenous analgesic and psychotic drugs

  • opiate receptors grow back pet mri near

    • •

    PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age

    References

    1. SAMHSA. National Survey on Drug Use and Health (NSDUH); 2015. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf.

    2. Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res. 2015;39:579–84.

      Article Google Scholar

    3. Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. 2014;75(s17):79–88.

      Article Google Scholar

    4. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Med Counc Alcohol. 1996;31:33–42.

      CAS Google Scholar

    5. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem. 2004;4:39–50.

      ArticleCAS Google Scholar

    6. Herz A

      •

      Abstract

      Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. They may have additional therapeutic utility also in the absence of opioid agonist drugs, but the onset and duration of action at brain MORs have been inadequately characterized to allow such projections. This study provides första characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone ledning to healthy volunteers in the absence of a competing opioid agonist. Fourteen participants were scanned twice using positron emission tomography (PET) and [11C]carfentanil, a selective MOR agonist radioligand. Concentrations of naloxone in plasma and MOR availability (relative to placebo) were monitored from 0 to 60 min and at 300–360 min post naloxone. Naloxone plasma concentrations peaked at ~20 min post naloxone, associated with slightly delayed development of brain MOR occupancy (half of p